Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neurotech International ( (AU:NTI) ) just unveiled an update.
Neurotech International, a clinical-stage biopharmaceutical company specialising in paediatric neurological disorders, is advancing NTI164, a proprietary CBDA-rich cannabinoid formulation targeting neuroinflammatory and immune pathways in conditions such as Autism Spectrum Disorder and PANDAS/PANS. The company will showcase its clinical progress and pipeline at the NWR Virtual Healthcare Conference on 25 March 2026, offering investors and stakeholders further insight into its late-stage ASD program and broader paediatric neurology strategy via a live presentation and subsequent replay access.
The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
More about Neurotech International
Neurotech International is a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders, centred on its broad-spectrum oral cannabinoid drug candidate NTI164. The company has reported clinically meaningful and statistically significant results from Phase II/III and Phase I/II trials in Autism Spectrum Disorder, PANDAS/PANS and Rett Syndrome, and has ethics clearance for a Phase III ASD study.
Average Trading Volume: 1,387,715
Technical Sentiment Signal: Sell
Current Market Cap: A$12.96M
Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.